What Supreme Court’s Myriad decision means for biopharma companies
On 13 June 2013, the US Supreme Court ruled that certain patent claims owned by Myriad Genetics, the US biotech company that holds the patents covering a test for breast-cancer-related genes (BRCA1 and BRCA2), are invalid as products of nature. The court held that a naturally occurring DNA segment is ‘a product of nature and […]